CellBion Co., Ltd. (KOSDAQ:308430)

Market Cap	231.39B +19.7%
Revenue (ttm)	2.08B -19.1%
Net Income	-8.54B
EPS	n/a
Shares Out	12.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,707
Open	17,940
Previous Close	19,170
Day's Range	16,900 - 18,410
52-Week Range	15,700 - 42,200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 13, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 55
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308430

Financial Performance

In 2025, CellBion's revenue was 1.95 billion, a decrease of -15.05% compared to the previous year's 2.29 billion. Losses were -7.57 billion, 4.23% more than in 2024.